<DOC>
	<DOC>NCT01353404</DOC>
	<brief_summary>The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.</brief_summary>
	<brief_title>Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy adults 2050 years of age Weight more than 55kg and within ±20% IBW(Ideal Body Weight) Voluntary written informed consent History or presence of significant renal, neurologic, pulmonary, endocrine, hematology, oncology, urologic, cardiovascular, musculoskeletal or psychiatric disease Drug allergies to fenofibrate Recent history or evidence of drug abuse Recent participation(within 2months) in other clinical studies Recent donation of blood(within 2months) or plasma(within 1months)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>